Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Catatonic Schizophrenia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Catatonic Schizophrenia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-000800-34 Sponsor Protocol Number: H8Y-MC-HBBI Start Date*: 2007-08-14
    Sponsor Name:Eli Lilly and Company Ltd.
    Full Title: A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia.
    Medical condition: Patients must have a diagnosis of Schizophrenia as defined in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (Disorganized, 295.10; Catatonic, 295.20; Paranoid, 295....
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039638 Schizophrenia, disorganised type PT
    9.1 10039637 Schizophrenia, catatonic type PT
    9.1 10039639 Schizophrenia, paranoid type PT
    9.1 10039640 Schizophrenia, residual type PT
    9.1 10052792 Schizophrenia, undifferentiated type PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024488-42 Sponsor Protocol Number: 2010-024488-42-PACS Start Date*: 2011-01-31
    Sponsor Name:Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Psychosisresearch
    Full Title: Pregabalin for anxiety comorbidity in patients with schizophrenia (PACS) - A Double-blinded Randomized Placebo Controlled Trial
    Medical condition: anxiety-comorbidity to schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10013387 Disorganized type schizophrenia LLT
    19.0 100000004873 10013386 Disorganised schizophrenia LLT
    19.0 100000004873 10007780 Catatonic schizophrenia LLT
    19.0 100000004873 10019364 Hebephrenic schizophrenia LLT
    19.0 100000004873 10033872 Paranoid schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-009215-22 Sponsor Protocol Number: BISCLOZ Start Date*: 2009-03-26
    Sponsor Name:Aalborg Psychiatric Hospital, Centre for Skizophrenia
    Full Title: “Treating clozapine-induced sinustachycardia (BISCLOZ).”
    Medical condition: Clozapine induced sinuatachycardia treated with bisoprolol.
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004873 10013387 Disorganized type schizophrenia LLT
    15.1 100000004873 10013386 Disorganised schizophrenia LLT
    15.1 100000004873 10019364 Hebephrenic schizophrenia LLT
    15.1 100000004873 10007780 Catatonic schizophrenia LLT
    15.1 100000004873 10033872 Paranoid schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-000479-11 Sponsor Protocol Number: 12396A Start Date*: 2008-07-21
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia
    Medical condition: Lu 31-130 is under development by H. Lundbeck A/S as an antipsychotic in the treatment of schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039639 Schizophrenia, paranoid type PT
    9.1 10039637 Schizophrenia, catatonic type PT
    9.1 10039638 Schizophrenia, disorganised type PT
    9.1 10052792 Schizophrenia, undifferentiated type PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008366-13 Sponsor Protocol Number: 3.0edition Start Date*: 2009-03-17
    Sponsor Name:Unit for Psychiatric Research
    Full Title: Comparison of the effects of Sertindole and Olanzapine on Cognition
    Medical condition: Cognitive deficits in patients with schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019364 Hebephrenic schizophrenia LLT
    9.1 10046150 Unspecified schizophrenia LLT
    9.1 10052792 Schizophrenia, undifferentiated type LLT
    9.1 10007780 Catatonic schizophrenia LLT
    9.1 10033877 Paranoid type schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022181-28 Sponsor Protocol Number: 13639A Start Date*: 2011-02-07
    Sponsor Name:H. Lundbeck A/S
    Full Title: A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039638 Schizophrenia, disorganised type PT
    14.0 10037175 - Psychiatric disorders 10039639 Schizophrenia, paranoid type PT
    14.0 10037175 - Psychiatric disorders 10052792 Schizophrenia, undifferentiated type PT
    14.0 10037175 - Psychiatric disorders 10039637 Schizophrenia, catatonic type PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020370-42 Sponsor Protocol Number: NN25310 Start Date*: 2011-01-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...
    Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001845-40 Sponsor Protocol Number: R092670-PSY-3005 Start Date*: 2005-08-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia
    Medical condition: Schizophrenia according to DSM-IV-TM [disorganized type (295.10), catatonic type (295.20), paranoid type (295.30), residual type (295.60) or undifferentiated type (295.90)]
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-006434-17 Sponsor Protocol Number: R092670PSY3007 Start Date*: 2007-05-03
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palm...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-007538-21 Sponsor Protocol Number: CYR-101C01 Start Date*: 2008-04-22
    Sponsor Name:CYRENAIC
    Full Title: A Multi-center, Inpatient and ambulatory, Phase 2, Double-blind, Randomised, Placebo-controlled Proof of Concept Study of CYR-101 in Patients with DSM-IV Schizophrenia
    Medical condition: Diagnosis of Schizophrenia in Male or female patients, as defined in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revised (DSM-IV TR, APA 2000) and confirmed by the St...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018405-12 Sponsor Protocol Number: RGH-MD-11 Start Date*: 2010-10-11
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: Evaluation of the Long-Term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients with Schizophrenia
    Medical condition: Schizophrenia is a lifelong disabling psychiatric disorder with a reported worldwide prevalence of about 1%.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001064 Acute schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002560-17 Sponsor Protocol Number: 25543 Start Date*: 2005-04-14
    Sponsor Name:NV Organon
    Full Title: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizop...
    Medical condition: Schizophrenia with predominant, persistent negative symptoms
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039626 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Prematurely Ended) SE (Completed) DE (Completed) CZ (Completed) GB (Completed) IT (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-020467-21 Sponsor Protocol Number: WN25309 Start Date*: 2010-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio en fase III multicéntrico aleatorizado, de 24 semanas, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de RO4917838 en pacientes estables c...
    Medical condition: Tratamiento de los síntomas negativos en pacientes con esquizofrenia tratados con antipsicóticos Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002048-29 Sponsor Protocol Number: RGH-MD-06 Start Date*: 2012-03-29
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-003560-62 Sponsor Protocol Number: R092670PSY3006 Start Date*: 2007-03-28
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schi...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) LT (Completed) DE (Completed) AT (Completed) FR (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-002342-11 Sponsor Protocol Number: D1449L00033 Start Date*: 2007-04-19
    Sponsor Name:Klinikum Fulda gAG
    Full Title: Multicenter study of neurotransmitters and neuropeptides in schizophrenia: A multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffer...
    Medical condition: Patients have to fulfill the diagnostic criteria of a schizophrenia according to DSM-IV.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005078-22 Sponsor Protocol Number: QUETIAPINKOGNSCHIZOPHR Start Date*: 2005-04-18
    Sponsor Name:Medical School of Hannover
    Full Title: Quetiapin: Zur Sicherheit, Verträglichkeit und zum Einfluss auf kognitive Funktionen bei Patienten/innen mit einer schizophrenen Psychose Quetiapine: safety and influence on cognitive functions i...
    Medical condition: Patients with schizophrenia, who are not in an acute state of psychosis at enrolment (PANSS score < 80) and who do not show criteria of moderate depression, but may show depression-like symptoms co...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017852-28 Sponsor Protocol Number: H8Y-MC-HBBM(a) Start Date*: 2010-05-04
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 versus Placebo in Patients with DSM-IVTR Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020470-42 Sponsor Protocol Number: WN25308 Start Date*: 2011-01-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...
    Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000053-27 Sponsor Protocol Number: MELIA Start Date*: 2020-07-09
    Sponsor Name:UMC Utrecht
    Full Title: The MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain.
    Medical condition: Antipsychotic-induced weight gain (AiWG)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA